13,367 Shares in AtriCure, Inc. $ATRC Purchased by Tactive Advisors LLC

Tactive Advisors LLC bought a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 13,367 shares of the medical device company’s stock, valued at approximately $374,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its holdings in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares in the last quarter. Scotia Capital Inc. grew its holdings in shares of AtriCure by 1.2% during the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after buying an additional 457 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of AtriCure by 6.6% during the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock worth $349,000 after buying an additional 543 shares in the last quarter. Captrust Financial Advisors raised its position in shares of AtriCure by 7.9% in the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock valued at $314,000 after buying an additional 579 shares during the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of AtriCure by 5.3% in the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after buying an additional 683 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ATRC. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Canaccord Genuity Group lifted their target price on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Weiss Ratings raised AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday, July 28th. Finally, Raymond James Financial set a $52.00 price objective on AtriCure in a report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

AtriCure Stock Performance

NASDAQ ATRC opened at $41.39 on Monday. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $43.18. The company has a 50-day moving average of $32.25 and a 200-day moving average of $31.33. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The company has a market cap of $2.11 billion, a P/E ratio of 197.10 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts predict that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Insider Activity at AtriCure

In related news, Director Maggie Yuen sold 3,500 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the transaction, the director directly owned 14,015 shares of the company’s stock, valued at approximately $538,456.30. This trade represents a 19.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of AtriCure stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the transaction, the insider owned 86,511 shares in the company, valued at $3,363,547.68. The trade was a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 47,246 shares of company stock worth $1,777,845. 4.00% of the stock is owned by corporate insiders.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.